AQST Stock Forecast & Price Target

Aquestive Therapeutics, Inc. is positioned favorably due to its advancements in the no-needle epinephrine market, which is anticipated to experience significant growth alongside the introduction of both oral and intranasal alternatives. The recent announcement from the FDA indicating that an AdCom is not required for the NDA of Anaphylm has resulted in a notable 43.77% increase in shares, suggesting strong investor confidence in the company’s product development trajectory. Additionally, the compelling data package submitted appears to have adequately addressed key concerns, paving the way for potential approval without requiring expert recommendations, thereby enhancing the outlook for Aquestive’s future revenue streams.

Aquestive Therapeutics faces significant downside risks that could negatively impact its stock performance, primarily stemming from the potential for unsuccessful development of its product AQST-109. Additionally, there are concerns regarding greater-than-expected revenue erosion from its licensed commercial products, which could hamper financial stability. The necessity to raise capital to bolster the company's balance sheet further complicates its financial outlook and raises concerns among investors.